Anti-Fibrinolytic Drugs - Lesotho

in Lesotho, a country Southern_Africa, is also part of the Anti-Fibrinolytic Drugs market.
In 2024, the projected revenue for this market is expected to reach US$337.20k.
Looking ahead, the revenue is anticipated to grow at an annual growth rate (CAGR 2024-2029) of 4.98%.
As a result, by 2029, the market volume is projected to reach US$429.90k.
In global comparison, it is worth noting that United States is expected to generate the highest revenue in this market.
In 2024, the projected revenue for the United States is estimated to be US$9.86bn.
Lesotho's market for anti-fibrinolytic drugs is witnessing a surge in demand due to the country's high prevalence of bleeding disorders.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

Anti-Fibrinolytic Drugs are gaining popularity in the pharmaceutical market due to their effectiveness in treating bleeding disorders. Lesotho, a small country in southern Africa, is also witnessing a surge in demand for these drugs.

Customer preferences: Lesotho has a high prevalence of bleeding disorders, such as hemophilia and von Willebrand disease, which has led to an increased demand for Anti-Fibrinolytic Drugs. The country's healthcare system is also expanding, and there is a growing awareness among the population regarding the availability of these drugs.

Trends in the market: The Anti-Fibrinolytic Drugs market in Lesotho is witnessing a trend towards the use of generic drugs. This is because generic drugs are cheaper than branded drugs, and they are equally effective. The government of Lesotho is also actively promoting the use of generic drugs to reduce the burden on the healthcare system.

Local special circumstances: Lesotho is a small country with a population of just over 2 million people. The country is heavily dependent on foreign aid to fund its healthcare system. This has led to a shortage of drugs in the country, including Anti-Fibrinolytic Drugs. However, the government is taking steps to address this issue by partnering with international organizations to increase the availability of drugs in the country.

Underlying macroeconomic factors: The economy of Lesotho is heavily dependent on the textile industry, which accounts for more than 50% of the country's exports. This has led to a lack of diversification in the economy, which makes it vulnerable to external shocks. However, the government is taking steps to diversify the economy by investing in other sectors such as agriculture and tourism. This is expected to create more job opportunities and increase the purchasing power of the population, which will further boost the demand for Anti-Fibrinolytic Drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.